Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ABCL
- Price
- 2.51
- Stock movement up
- +0.07 (2.87%)
- Company name
- Abcellera Biologics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Markedsverdi
- 741.37M
- Ent verdi
- 929.46M
- Pris/omsetning
- 22.49
- Pris/bok
- 0.69
- Utbytte avkastning
- -
- Utbytte vekst
- -
- Vekst år
- -
- FCF-utbetaling
- -
- Etterfølgende P/E
- -
- Fremtidig P/E
- -
- PEG
- -
- EPS-vekst
- -
- 1 års avkastning
- -33.07%
- 3 års avkastning
- -31.24%
- 5 års avkastning
- -
- 10 års avkastning
- -
Sist oppdatert: 2025-06-10
iO Charts is a Seeking Alpha partner
The following slide deck was published by AbCellera Biologics Inc.
9. mai 2025
iO Charts is a Seeking Alpha partner
UTBYTTE
ABCL betaler ikke utbytte
iO Charts is a Seeking Alpha partner
AbCellera Biologics Inc. (NASDAQ:ABCL) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ETCompany ParticipantsTryn Stimart - Chief Legal and Compliance...
9. mai 2025
iO Charts is a Seeking Alpha partner
VERDSETTELSE
Verdsettelsesforhold
Loading...
Verdsettelsesforhold-data
| Etterfølgende P/E | - |
| Pris til OCF | - |
| Pris til FCF | - |
| Pris til EBITDA | - |
| EV i forhold til EBITDA | - |
Verdsettelse (Salg/Bokført verdi)
Loading...
Verdsettelse (Salg/Bokført verdi) data
| Pris til omsetning | 22.49 |
| Pris til bok | 0.69 |
| EV i forhold til salg | 28.20 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
ØKONOMI
Per aksje
Loading...
Per aksje-data
| Gjeldende aksje antall | 295.37M |
| EPS (TTM) | -0.60 |
| FCF per aksje (TTM) | -0.67 |
Resultatregnskap
Loading...
Resultatregnskap-data
| Inntekter (TTM) | 32.96M |
| Bruttofortjeneste (TTM) | -59.24M |
| Driftsinntekter (TTM) | -308.06M |
| Netto inntekt (TTM) | -175.80M |
| EPS (TTM) | -0.60 |
| EPS (1 år fremover) | -0.68 |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | -179.73% |
| Driftsmargin (TTM) | -934.58% |
| Fortjenestemargin (TTM) | -533.32% |
Balanse
Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
| Kontanter | 126.64M |
| Netto fordringer | 63.24M |
| Samlede omløpsmidler | 742.88M |
| Goodwill | 47.81M |
| Immaterielle eiendeler | 52.58M |
| Eiendom, anlegg og utstyr | 0.00 |
| Sum eiendeler | 1.39B |
| Leverandørgjeld | 34.80M |
| Kortsiktig/nåværende langsiktig gjeld | 71.40M |
| Sum kortsiktig gjeld | 79.57M |
| Sum gjeld | 314.73M |
| Aksjonærenes egenkapital | 1.08B |
| Netto varige driftsmidler | 0.00 |
Kontantstrøm
Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
| Kontantstrøm fra drift (TTM) | -119.66M |
| Kapitalutgifter (TTM) | 76.88M |
| Fri kontantstrøm (TTM) | -196.54M |
| Utbetalt utbytte (TTM) | 0.00 |
Finansielle inntekter
Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
| Egenkapitalavkastning | -16.31% |
| Avkastning på eiendeler | -12.62% |
| Avkastning på investert kapital | -16.23% |
| Kontantavkastning på investert kapital | -18.14% |
AbCellera faces challenges as it shifts to internal development, impacting revenue. It retains a large cash position. Read here for an analysis of ABCL stock.
17. april 2025
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
AKSJEINFORMASJON
Aksjediagram
Loading...
Aksjekurs-data
| Åpning | 2.49 |
| Daglig høy | 2.53 |
| Daglig lav | 2.45 |
| Daglig volum | 4.55M |
| Tidenes høyeste | 53.20 |
| 1 år analytikerestimat | 12.29 |
| Beta | 0.35 |
| EPS (TTM) | -0.60 |
| Utbytte per aksje | - |
| Ex-div dato | - |
| Neste dato for resultatpresentasjon | - |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| ABCL | S&P500 | |
| Nåværende prisfall fra toppnotering | -95.28% | -2.16% |
| Høyeste prisfall | -96.37% | -56.47% |
| Dato for høyeste fall | 8 Apr 2025 | 9 Mar 2009 |
| Gj.snittlig fall fra topp | -79.43% | -11.05% |
| Gj.snittlig tid til ny topp | 225 days | 12 days |
| Maks tid til ny topp | 1094 days | 1805 days |
AbCellera faces challenges with a sharp revenue decline and share drop. With $840M liquidity, its pivot to drug development makes 2026 a critical year. See more.
15. mars 2025
iO Charts is a Seeking Alpha partner
AbCellera Biologics Inc. (NASDAQ:ABCL) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ETCompany ParticipantsTryn Stimart - Chief Legal and...
28. februar 2025
iO Charts is a Seeking Alpha partner
SELSKAPSOPPLYSNINGER
Markedsverdi
741.37M
Markedsverdi kategori
Small-cap
Beskrivelse
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Ansatte
586
Nettsted
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Land
USA
By
Aksjetype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Seeking AlphaPressemeldinger
AbCellera Biologics Inc. shifts focus to developing wholly owned candidates and trades near net cash on its balance sheet. Find out why ABCL stock is a Hold.
23. desember 2024
AbCellera Biologics Inc. (NASDAQ:ABCL) Q3 2024 Earnings Conference Call November 4, 2024 5:00 PM ETCompany ParticipantsTryn Stimart - Chief Legal and...
5. november 2024
The following slide deck was published by AbCellera Biologics Inc.
4. november 2024
AbCellera is shifting focus to its internal drug pipeline, notably ABCL575. Learn more about ABCL stock and its potential value of over $1B.
14. oktober 2024
AbCellera's Q2 2024 showed a revenue decline, increased R&D expenses, and a growing number of molecules in clinical trials. Read more on ABCL stock here.
23. august 2024
AbCellera Biologics Inc. (NASDAQ:ABCL) Q2 2024 Earnings Conference Call August 6, 2024 5:00 PM ETCompany ParticipantsTryn Stimart - Chief Legal and...
7. august 2024
The following slide deck was published by AbCellera Biologics Inc.
7. august 2024
iO Charts is a Seeking Alpha partnerNeste side